| Status: Under consideration by AWMSG Scrutiny Panel | |
Treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. |
|
Medicine details |
|
| Medicine name | bimekizumab (Bimzelx®) |
| Formulation | subcutaneous injection |
| Reference number | 4510 |
| Indication | As above |
| Company | UCB Pharma Ltd |
| BNF chapter | Skin |
| Assessment type | Under consideration |
| Status | Under consideration by AWMSG Scrutiny Panel |
| Scrutiny Panel meeting date | 19/06/2025 |